Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 4/20 | 0.42 |
| ▸ | PDE4A | P27815 | 2/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.40 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.39 |
| ▸ | TUBB | P07437 | 1/20 | 0.39 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.39 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.39 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.39 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.39 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.39 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.39 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.39 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.39 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.39 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.39 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.39 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.39 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL470124 | 0.83 | CA2 (0.54) | PDE4ATUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL31277237 | 0.83 | CA2 (0.54) | PDE4ATUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL28651200 | 0.81 | PDE4A (0.35) | PDE4BPDE4APDE4CPDE4DALDH1A1 | |
| SCHEMBL16978288 | 0.80 | NPSR1 (0.37) | PDE4BALDH1A1GAAAPPCSNK2A1 | |
| SCHEMBL16978291 | 0.80 | STK17B (0.39) | PDE4BPDE4APDE4CPDE4DCA2 | |
| SCHEMBL15197105 | 0.78 | CSNK2A1 (0.33) | ACHEALDH1A1HPGDCSNK2A1 | |
| SCHEMBL6112972 | 0.78 | TSHR (0.39) | MAPTSMN1; SMN2CSNK2A1 | |
| SCHEMBL10196610 | 0.78 | ACHE (0.68) | PDE4BPDE4APDE4CPDE4DACHE | |
| SCHEMBL13791695 | 0.78 | CA12 (0.68) | CA2CA12CA1CA7CA9 | |
| SCHEMBL24460269 | 0.76 | SLC6A4 (0.49) | ACHEMAPTHPGDCSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113563244-B | Substituted aza five-membered ring compound and application thereof in medicine | 广东东阳光药业股份有限公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-113563245-B | Substituted pyrrolidines and their use in medicine | 广东东阳光药业股份有限公司 | 2024-10-15 | — | — | CN | disclosed |
| CN-116354992-A | PDE4 inhibitor and application thereof in medicines | 广东东阳光药业有限公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-113563245-A | Substituted pyrrolidine compounds and application thereof in medicines | 广东东阳光药业有限公司 | 2021-10-29 | — | — | CN | disclosed |
| CN-113563244-A | Substituted aza five-membered ring compound and application thereof in medicine | 广东东阳光药业有限公司 | 2021-10-29 | — | — | CN | disclosed |
| US-20090118270-A1 | PHOSPHODIESTERASE 4 INHIBITORS | TALAMAS FRANCISCO XAVIER | 2009-05-07 | — | — | US | disclosed |
| EP-1581471-B9 | CYCLOPENTENONE DERIVATIVES FOR CANCER THERAPY | DABUR RES FOUNDATION (IN) | 2008-08-13 | — | — | EP | disclosed |
| EP-1581471-B1 | CYCLOPENTENONE DERIVATIVES FOR CANCER THERAPY | DABUR RES FOUNDATION (IN) | 2008-04-16 | — | — | EP | disclosed |
| EP-1888528-A2 | PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceuticals Corporation (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20070049611-A1 | Phosphodiesterase 4 inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-01 | — | — | US | disclosed |
| US-7179937-B2 | Cyclopentenone derivatives for cancer therapy | DABUR RESEARCH FOUNDATION (IN) | 2007-02-20 | — | — | US | disclosed |
| WO-2006135828-A2 | TRISUBSTITUTED AMINES AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-12-21 | — | — | WO | disclosed |
| EP-1581471-A1 | CYCLOPENTENONE DERIVATIVES FOR CANCER THERAPY | Dabur Research Foundation (IN) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004056738-A1 | CYCLOPENTENONE DERIVATIVES FOR CANCER THERAPY | DABUR RESEARCH FOUNDATION (IN) | 2004-07-08 | — | — | WO | disclosed |
| US-20030229146-A1 | Cyclopentenone derivatives for cancer therapy | DABUR RESEARCH FOUNDATION | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049611-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE3B, PDE4B | PDE4B 3/4885PDE4A 1/4885PDE4C 7/4885 |
| US-20090118270-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE3B, PDE4B | PDE4B 3/4885PDE4A 1/4885PDE4C 7/4885 |
| US-20030229146-A1 | Cyclopentenone derivatives for cancer therapy | MCL1, DLD, PYCR1 | PDE4B 1301/4885PDE4A 1287/4885PDE4C 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.